Aspirin and salicylate in respiratory disease

Rhinology

Volumn 51, Issue 3, 2013, Pages 195-205

  Mitchell, James E ^a,b   Skypala, Isabel ^c  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aspirin; Aspirin desensitisation; Asthma; Chronic rhino sinusitis; Salicylate

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID DERIVATIVE;

ASPIRIN EXACERBATED RESPIRATORY DISEASE; DESENSITIZATION; HUMAN; IMMUNOLOGY; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ASTHMA, ASPIRIN-INDUCED; DESENSITIZATION, IMMUNOLOGIC; HUMANS; SALICYLATES;

EID: 84881579141     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: 10.4193/Rhino12.144     Document Type: Review

References (78)

1. Szczeklik A, Stevenson DD: Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol. 1999; 104: 5-13.
2. Shaker M, Lobb A, Jenkins P, O'Rourke D, Takemoto SK, Sheth S et al. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2008; 121: 81-87.
3. Jenkins C, Costello J, Hodge L: Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004; 328: 434.
4. Settipane GA. Aspirin sensitivity and allergy. Biomed Pharmacother. 1988; 42: 493-498
5. Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps and chronic sinusitis. Ann Allergy Asthma Immunol. 2008; 100: 420-425.
6. Szczeklik A, Nizankowska E, Duplaga M. Natural History of aspirin-induced asthma. Eur Respir J. 2000; 16: 432-436.
7. Berges-Gimeno M, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2002; 89: 474-478.
8. Yamashita T, Tsuyi H, Maeda N, Tomoda K, Kumazawa T. Etiology of nasal polyps associated with aspirin-sensitive asthma. Rhinology. 1989; 8: 15-24.
9. Nasser SM, Pfister R, Christie PE, et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Resp Crit Care Med. 1996; 153: 90-96.
10. Daffern PJ, Muilenburg D, Hugli TE, Stevenson DD. Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol. 1999; 104: 559-564.
11. Hamad AM, Sutcliffe AM, Knox AJ. Aspirininduced asthma:clinical aspects, pathogenesis and management. Drugs. 2004; 64: 2417-2432.
12. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an alleic variant associated with aspirin-intolerant asthma. Am J Respir Mol Biol. 2000; 23: 290-296.
13. Sousa A, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med. 2002; 347: 1524-1526.
14. Bochenek G, Nagraba K, Nizankowska E, Szczeklik A. A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol. 2003; 111: 743-749.
15. Pierzchalska M, Szabo Z, Sanak M, Soja J, Szczeklik A. Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients with special reference to aspirin-induced asthma. J Allergy Clin Immunol. 2003; 111: 1041-1048.
16. Jinnai N, Sakagami T, Sekigawa T, Kakihara M, Nakajima T, Yoshida K, et al. Polymorphisms in the prostaglandin E2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. Hum Mol Genet. 2004; 13: 3203-3217.
17. Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Alllergy. 1988; 18: 15-20.
18. Jeffreys D. Aspirin: The story of a wonder drug. 2004 London: Bloomsbury Publishing.
19. Baxter G, Paterson J, Wiles D, Graham A, Shirastava R. Salicylic acid: the spice of life? Proc Nutr Soc. 2005; 64: 64A.
20. Paterson J, Baxter G, Lawrence J, Duthie G. Is there a role for dietary salicylates in health? Proc Nutr Soc. 2006; 65: 93-96.
21. Moore-Robinson M, Warin RP. Effect of salicylates in urticaria. Br Med J. 1967; 4: 262-264.
22. Douglas HM. Dietary treatment of patients with chronic urticaria and intolerance to aspirin and food additives. Dermatologica. 1977; 154: 308-310.
23. Juhlin L. Recurrant urticaria: Clinical investigation of 330 patients. Br J Dermatol. 1981; 104: 369-381.
24. McDonald JR, Mathieson DA, Stevenson DD. Aspirin intolerance in asthma. detection by oral challenge. J Allergy. 1972; 50: 198-207.
25. Hare LG, Woodside JV, Young IS. Dietary salicylates. J Clin Pathol. 2003; 56: 649-650.
26. Amann R, Peskar BA. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol. 2002; 447: 1-9.
27. Corder EH, Buckley CE. Aspirin, salicylate, sulfite and tartrazine-induced bronchoconstriction. Safe doses and case definition in epidemiological studies. J Clin Epidemiol. 1995; 48: 1269-1275.
28. Dahlén B, Boréus LO, Anderson P, Andersson R, Zetterström O. Plasma acetylsalicylic acid and salicylic acid levels during aspirin provocation in aspirin-sensitive subjects. Allergy. 1994; 49: 43-49.
29. Baenkler H-W. Salicylate Intolerance. Dtsch Arztebl Int. 2008; 105: 137-142.
30. Samter M, Beers RF. Concerning the nature of intolerance to aspirin, J Allergy. 1967; 40: 281-293.
31. Picado C, Fernandez-Morata JC, Juan M, Roca-Ferrer J, Fuentes M, Xaubet A, Mullol J. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am Resp Crit Care Med. 1999; 160: 291-296.
32. Swain AR, Dutton SP, Truswell AS. Salicylates in Foods. J Am Diet Assoc. 1985; 85: 950-960.
33. Venema DP, Hollman PCH, Janssen KPLTM, Katan MB. Determination of acetylsalicylic acid and salicylic acid in foods, using HPLC with fluorescence detection. J Agric Food Chem. 1996; 44: 1762-1767.
34. Scotter MJ, Roberts DPT, Wilson LA, Howard FAC, Davis J, Mansell N. Free salicylic acid and acetyl salicylic acid content of foods using gas chromatography-mass spectrometry. Food Chem. 2007; 105: 273-279.
35. Wood A, Baxter G, Paterson J, Thies F, Duthie G. Comparison of methods to determine salicylic acid content of fruit juices. Proc Nutr Soc. 2005; 64: 87A.
36. Janssen KTLPM, Hollman PCH, Venema DP, van Staveren WA, Katan MB. Salicylates in Foods. Nut Reviews. 1996; 54: 357-359.
37. Baxter G J, Graham AB, Lawrence JR, Wiles D, Paterson JR. Salicylic acid in soups prepared from organically and non-organically grown vegetables. Eur J Nutr. 2001; 40: 289-292.
38. Heiska S, Rousi M, Turtola S, Meier B, Tirkkonen V, Julkunen-Titto R. The effect of genotype and cultivation method on the total salicylate yield of dark leaved willows. Plant Medica. 2005; 71: 1134-1139.
39. Paterson JR, Srivastava R, Baxter GJ, Graham AB, Lawrence JR. Salicylic acid content of spices and its implications. J Agric Food Chem. 2006; 54: 2891-2896.
40. Amman R, Peskar BA. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol. 2002; 447: 1-9.
41. Janssen KTLPM, Hollman PCH, Reichmann E, Venema DP, van Staveren WA, Katan MB. Urinary salicylate excretion in subjects eating a variety of diets shows the amounts of bioavailable salicylates in foods are low. Am J Clin Nutr. 1996; 64: 743-747.
42. Lawrence JR, Peter R, Baxter G, Robson J, Graham AB, Paterson JR. Urinary excretion of salicyluric and salicylic acids by non-vegetarians, vegetarians and patients taking low-dose aspirin. J Clin Pathol. 2003; 56: 651-653.
43. Nizankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J. 2000; 15: 863-869.
44. Alonso-Llamazares A, Martinez-Cocera C, Dominguez-Ortega J, Robledo-Echarren T, Cimarra-Alvarez M, Mesa del CM. Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirininduced asthma (AIA). Allergy. 2002; 57: 632-635.
45. Gamboa P, Sanz ML, Caballero MR, Urrutia I, Antépara I, Esparza R, et al. The flow-cytometric determination of basophil activation induced by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hyper-sensitivity syndrome. Clin Exp Allergy. 2004; 34: 1448-1457.
46. Kowalski ML, Ptasinska A, Jedrzejczak M, Bienkiewicz B, Cieslak M, Grzegorczyk J, et al. Aspirin triggered 15 HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest). Allergy. 2005; 60: 1139-1145.
47. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczynska M, Picado C, Scadding G, et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy. 2007; 62: 1111-1118.
48. Dahlen S, Malstrom K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist. A randomised, double-blind, placebo-controlled trial. Am J Resp Crit Care Med. 2002; 165: 9-14.
49. Dahlen S, Nizankowska E, Szczeklik A, et al. The benefits of adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Resp Crit Care Med. 1998; 157: 1187-1194.
50. Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007; 98: 172-174.
51. Stevenson DD, Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol. 2006; 118: 801-804.
52. Zeiss CR, Lockey RF. Refractory period toaspirin in a patient with aspirin-induced asthma. J Allergy Clin Immunol. 1976; 7: 440-448.
53. Stevenson DD, Simon RA, Mathison DA. Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol. 1980; 66: 82-88.
54. Stevenson DD, Pleskow WW, Simon RA, Mathison DA, Lumry WR, Schatz M, et al. Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol. 1984; 73: 500-507.
55. Sweet JM, Stevenson DD, Simon RA, Mathison DA. Long-term effects of aspirin desensitization-treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol. 1990; 85: 59-65.
56. Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol. 1996; 98: 751-758.
57. McMains KC, Kountakis SE. Medical and surgical considerations in patients with Samter's triad. Am J Rhinol. 2006; 20: 573-576.
58. Berges-Gimeno MP, Simon RA, Stevenson DD: Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003; 111: 180-186.
59. Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2007; 119: 157-164.
60. Rozsasi A, Polzehl D, Deutschle T, Smith E, Wiesmiller K, Riechelmann H, et al. Longterm treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy. 2008; 63: 1228-1234.
61. Forer B, Kivity S, Sade J, Landsberg R. Aspirin desensitization for ASA triad patients - a prospective study of the rhinologist's perspective. Rhinology. 2011; 49: 95-100.
62. Berges-Gimeno MP, Simon RA, Stevenson DD: Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2003; 90: 338-341.
63. Williams AN, Simon RA, Woessner KM, Stevenson DD. The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol. 2007; 120: 273-277.
64. Stevenson DD. Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Reports. 2009; 9: 155-163.
65. Williams AN, Woessner KM. The clinical effectiveness of aspirin desensitization in chronic Rhinosinusitis. Curr Allergy Asthma Reports. 2008; 8: 245-252.
66. Patriarca G, Bellioni P, Nucera E, Schiavano D, Papa G, Schino G. et al. Intranasal treatment with lysine acetylsalicylate in patients with nasal polyposis. Ann Allergy. 1991; 67: 588-592.
67. Scadding GK, Hassab M, Darby YC, Lund VJ, Freedman A. Intranasal lysine aspirin in recurrent nasal polyposis. Clin Otolaryngol Allied Sci. 1995; 20: 561-563.
68. Nucera E, Schiavino D, Milani A, Del Ninno M, Misuraca C, Buonomo A, et al. Effects of lysine-acetylsalicylate (LAS) treatment in nasal polyposis: two controlled long term prospective follow up studies. Thorax. 2000; 55: S75-S78.
69. Parikh AA, Scadding GK. Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial. Laryngoscope. 2005; 115: 1385-1390.
70. Ogata N, Darby Y, Scadding G: Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma. J Laryngol Otol. 2007; 121: 1156-1160.
71. Slavin RG, Spector SL, Bernstein IL, Kaliner MA, Kennedy DW, Virant FS, et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol. 2005; 116: S13-S47.
72. Fokkens W, Lund V, Mullol J, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2007. Rhinology. 2007; 45 (Suppl20): 1-139.
73. Fokkens W, Lund V, Mullol J, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2007. Rhinology. 2012; 50 (Suppl23): 1-298.
74. Lee JY, Simon RA. Does it make sense to "desens"? Aspirin desensitization in the treatment of chronic rhinosinusitis. Curr Allergy Asthma Reports. 2006; 6: 183-184.
75. Vaidyanathan S, McKean S, Lipworth BJ. Aspirin desensitisation therapy for aspirin-intolerant chronic rhinosinusitis. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No: CD008124. DOI:10.1002/14651858.CD008124.
76. NHS Economic Evaluation Database. Available at: http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008000223
77. Hope AP, Woessner KA, Simon RA, Stevenson DD. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2008; 123: 406-410.
78. Williams AN, Simon RA, Woessner KM, Stevenson DD. The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol. 2007; 120: 273-277.